LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives

Farzaneh Atashrazm1
Nicolas Dzamko2

1Neuroscience Research Australia, Randwick; 2School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia

Abstract: Major advances in understanding how genetics underlies Parkinson’s disease (PD) have provided new opportunities for understanding disease pathogenesis and potential new targets for therapeutic intervention. One such target is leucine-rich repeat kinase 2 (LRRK2), an enigmatic enzyme implicated in both familial and idiopathic PD risk. Both academia and industry have promoted the development of potent and selective inhibitors of LRRK2, and these are currently being employed to assess the safety and efficacy of such compounds in preclinical models of PD. This review examines the evidence that LRRK2 kinase activity contributes to the pathogenesis of PD and outlines recent progress on inhibitor development and early results from preclinical safety and efficacy testing. This review also looks at some of the challenges remaining for translation of LRRK2 inhibitors to the clinic, if indeed this is ultimately warranted. As a disease with no current cure that is increasing in prevalence in line with an aging population, there is much need for developing new treatments for PD, and targeting LRRK2 is currently a promising option.

Keywords: synuclein, inflammation, lysosome, Rab, inhibitor, autophagy

Introduction
Parkinson’s disease

As global populations age, neurodegenerative diseases are rapidly emerging as a major human health burden. As the most common neurodegenerative movement disorder, Parkinson’s disease (PD) contributes substantially to this burden. Defined pathologically by the accumulation of proteinaceous inclusions in the brain, termed Lewy bodies, PD results in neuronal dysfunction and progressive loss of dopamine-producing neurons located in the substantia nigra pars compacta region of the midbrain. Declining dopamine levels are responsible for the classical PD motor symptoms of resting tremor, postural instability, rigidity, and slow movement. To a certain extent, dopamine replacement medication can improve motor function in PD patients, but treatment remains purely symptomatic with no currently available cures or disease-modifying therapies. Moreover, current therapies do not adequately address the nonmotor symptoms that manifest with PD such as sleep disorders, hallucinations, gastrointestinal dysfunction, depression, cognitive decline leading to dementia, and loss of smell. Collectively, the motor and nonmotor symptoms combine over decades to produce a progressively debilitating disease, the exact cause(s) of which have remained elusive for almost 200 years. A wealth of data, however, has implicated key biological processes that may contribute to neuronal dysfunction. Chief among these are autophagy/lysosomal dysfunction,1,2
mitochondrial dysfunction,\textsuperscript{3,4} and inflammation,\textsuperscript{5,6} all of which are highly integrated and complexly regulated. Unfortunately, due to a lack of disease biomarkers, studying the early phase of PD is not currently possible. Consequently, delineating which biological processes are causes, or indeed consequences, of up to decades of disease is exceedingly difficult. Knowing that in some instances PD can be caused by missense mutations in a number of proteins may give further clues to help unravel the complex etiology of PD.

PD genetics
Over the past two decades, new information describing how genetics may influence PD susceptibility has been uncovered. Inherited mutations that cause familial PD have been identified in \textsuperscript{18} genes, collectively accounting for \textasciitilde10\% of all PD.\textsuperscript{7–9} Familial PD mutations can be inherited in either a recessive or autosomal dominant manner and are predominantly missense mutations altering the function(s) of the proteins they encode. There is consequently much interest in delineating the biological function of these PD-implicated proteins and identifying converging disease-causing pathways. This is not trivial, however, as a number of familial PD genes cause disease in a manner atypical from the common idiopathic form. For example, mutations in \textit{Parkin} are the most common cause of recessively inherited PD, but Parkin-associated PD presents with a much earlier onset and slower disease progression than idiopathic PD.\textsuperscript{10,11} By way of contrast, mutations in \textit{α-synuclein} are often associated with a more aggressive form of PD.\textsuperscript{12} Indeed, clinical studies have long suggested heterogeneity in PD, suggesting caution in extrapolating from familial PD to the more common idiopathic form of PD. In the case of leucine-rich repeat kinase 2 (LRRK2), however, where the LRRK2 mutations are the most common cause of autosomal-dominant PD, there is substantial overlap with idiopathic PD in terms of clinical symptoms.\textsuperscript{13,14} Thus, it is plausible that understanding LRRK2 at least may provide insight into both familial and idiopathic PD.

The connection between LRRK2 and idiopathic PD is further strengthened by results from large-scale genome wide association studies and subsequent meta-analyses, suggesting that \textit{LRRK2} polymorphisms are linked to increased risk of idiopathic PD.\textsuperscript{15–17} Indeed, of the \textasciitilde18 familial PD genes, only those encoding LRRK2 and \textit{α-synuclein} are consistently associated with idiopathic PD risk. The polymorphisms identified by genome wide association studies are largely in the noncoding regions of the \textit{LRRK2} gene and are thus different from the missense mutations that cause familial PD. How these polymorphisms contribute to PD risk is unknown, but it is possible they may affect the transcriptional regulation of the \textit{LRRK2} gene and thus protein production. Being genetically linked to both familial and idiopathic forms of PD has elevated interest in LRRK2, but perhaps even more so, is that as a protein kinase, LRRK2 may present a readily druggable target. The majority of LRRK2 research has therefore focused on the enzyme’s catalytic kinase activity. Pubmed was used to search the literature with a focus on the past 5 years of LRRK2 research.

Evidence linking LRRK2 kinase activity to PD
Pathogenic LRRK2 mutations and kinase activity
By far, the most common pathogenic LRRK2 mutation is the substitution of glycine at position 2019 to serine (G2019S mutation). This mutation lies in a conserved part of the protein kinase domain that commences the activation loop, which, as the name implies, regulates catalytic enzyme activity (Figure 1). The neighboring I2020T mutation also lies in the kinase domain, while the other pathogenic LRRK2 mutations lie in either the Ras-like GTPase domain (R1441C/G/H), or the C-terminal of Ras domain (Y1699C) that links the GTPase and kinase domains of LRRK2.\textsuperscript{18} Studies using autophosphorylation as a surrogate readout of LRRK2 activity suggest a common mechanism across pathogenic mutations to increase kinase activity.\textsuperscript{19,20} In vitro kinase assays with model LRRK2 peptide substrates confirm that the G2019S mutation results in a direct two–threefold increase in kinase activity.\textsuperscript{21} The recent identification of Rab family GTPases as LRRK2 substrates has also allowed for in vivo assessment of LRRK2 activity by measuring Rab phosphorylation. Consistent with autophosphorylation results, pathogenic LRRK2 mutations increased Rab phosphorylation in cells.\textsuperscript{22} However, in vitro, only G2019S LRRK2 can increase Rab phosphorylation, a result consistent across in vitro kinase assay peptide substrates.\textsuperscript{22,23} This suggests distinct mechanisms by which the G2019S mutation directly increases LRRK2 kinase activity, presumably due to its location in the kinase domain, but other pathogenic mutations indirectly increase LRRK2 kinase activity. Exactly how mutations outside of G2019S increase kinase activity remains to be elucidated, but likely involves the complex interplay between the GTPase and kinase domains that has been observed. For example, a number of autophosphorylation sites in the GTPase domain may affect GTPase activity,
and conversely, modulating GTPase activity has effects on LRRK2 kinase activity. Understanding this complex domain cross-talk will likely be important for understanding LRRK2 function, but nonetheless, biochemical evidence from mutation studies suggests a key role for LRRK2 kinase activity in mediating PD pathogenesis.

**Increased kinase activity and LRRK2 pathobiology**

Early studies in cells, flies, worms, and transgenic animal models demonstrated that overexpression of G2019S LRRK2 could induce or potentiate PD-like neurodegenerative phenotypes, particularly in regard to neuronal toxicity, dopamine transmission, and neurite morphology. In most instances, overexpression of G2019S LRRK2 was compared to wild-type (WT) LRRK2, the overexpression of which induced little to no phenotype in most models studied. This led to a concept that the kinase activity increasing LRRK2 G2019S mutation at least, may impart a new toxic gain of function. However, any mechanism by which increased LRRK2 kinase activity actually mediates PD-associated toxicity remains unclear. Indeed, even the normal function of LRRK2 remains unclear. The majority of reports though suggest roles for LRRK2 in the highly integrated pathways of inflammation, autophagy/lysosomal function and mitochondrial function, all of which are also highly implicated in PD pathogenesis.

**The development of potent and selective LRRK2 inhibitors**

The discovery of pathogenic LRRK2 mutations in 2004 opened a new opportunity for PD therapy, with a focus on developing LRRK2 inhibitors. However, drug development has proven to be highly challenging with a lack of knowledge regarding LRRK2 biology, blood–brain barrier (BBB) permeability limitation, and a lack of preclinical models that faithfully recapitulate PD phenotypes, among many challenging factors that need to be overcome to develop drugs for potential first-in-human trials.

**Early nonselective compounds**

The earliest compounds tested for blocking LRRK2 activity were largely nonselective pan-kinase inhibitors, mostly derived from cancer research. In 2009, Gygi and Giasson examined the effect of 120 kinase inhibitors on WT and G2019S LRRK2, five of which were reported to be favorable candidates for LRRK2 inhibition; JAK3 inhibitor VI, K252A, staurosporine, Su-11248, and Ro-31-8220. Staurosporine is a natural indolinone component derived from a bacterium and inhibits a large number of protein kinases through prevention of adenosine triphosphate binding to the kinase. Among the five best targets, staurosporine was the most potent compound with an IC₅₀ of 2 and 1.8 nM for WT and G2019S LRRK2, respectively. Despite its high potency, its nonselectivity limits its usage. In the following studies,
many such pan-kinase inhibitors were analyzed for their inhibitory activity against LRRK2, among which a wide range of nonselective LRRK2 inhibitors were described, including the tyrosine kinase inhibitor imatinib, mitogen-activated protein kinase kinase inhibitors PD98059 and U0126, Z8205, sunitinib, the Raf kinase inhibitors sorafenib and GW5074, and the anaplastic lymphoma kinase inhibitor, TAE684. Although many of these nonselective kinase inhibitors have a significant effect on LRRK2 activity in cells and rodents, their relatively poor potency, multiple kinase targets, and poor pharmacokinetic profiles limited their clinical application, necessitating further development of more favorable compounds.

First-generation selective compounds

LRRK2-IN-1 was first among a number of compounds with an improved potency and selectivity profile (Table 1). The selectivity of LRRK2-IN-1 was robustly characterized using a high-throughput kinase profiling screening of 442 kinases. Having a strong binding affinity to both WT and G2019S mutant LRRK2 in addition to a good pharmacokinetic exposure in mice with a half-life of 4.5 hours, LRRK2-IN-1 appeared to be a promising agent for PD therapeutic studies. However, its bulky size and impermeability through the BBB limited its use in vivo. Moreover, LRRK2-IN-1 appears to cause a number of off-target effects relating to inflammatory pathways, which confounds its use in this emerging area of LRRK2 biology.

CZC-54252 and CZC-25146 are other early “tool” inhibitors with improved specificity and potency against LRRK2.

Table 1 Characteristics and potency of selective LRRK2 inhibitors

<table>
<thead>
<tr>
<th>References</th>
<th>Compound</th>
<th>LRRK2 IC50 (nM)</th>
<th>Brain permeability</th>
<th>Half-life (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>G2019S</td>
<td>A2016T</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deng et al (2011)50</td>
<td>LRRK2-IN-1</td>
<td>13.0</td>
<td>6.0</td>
<td>2450</td>
</tr>
<tr>
<td>Ramsden et al (2011)52</td>
<td>CZC-54252</td>
<td>1.28</td>
<td>1.85</td>
<td>N/A</td>
</tr>
<tr>
<td>Ramsden et al (2011)52</td>
<td>CZC-25146</td>
<td>4.76</td>
<td>6.87</td>
<td>N/A</td>
</tr>
<tr>
<td>Mice: 1 (p.o. 5 mg/kg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choi et al (2012)53</td>
<td>HG-10-102-1</td>
<td>20.3</td>
<td>3.2</td>
<td>153.7</td>
</tr>
<tr>
<td>Reith et al (2012)54</td>
<td>GSK2578215A</td>
<td>10.9</td>
<td>8.9</td>
<td>81.1</td>
</tr>
<tr>
<td>Hatcher et al (2015)55</td>
<td>JH-II-127</td>
<td>6.6</td>
<td>2.2</td>
<td>47.7</td>
</tr>
<tr>
<td>Hatcher et al (2015)55 and Estrada et al (2012)56</td>
<td>GNE-7915</td>
<td>9</td>
<td>--</td>
<td>466</td>
</tr>
<tr>
<td>Estrada et al (2014)57</td>
<td>GNE-0877</td>
<td>3</td>
<td>--</td>
<td>N/A</td>
</tr>
<tr>
<td>Estrada et al (2014)57</td>
<td>GNE-9605</td>
<td>19</td>
<td>--</td>
<td>N/A</td>
</tr>
<tr>
<td>Dog: 0.78</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHP: 2.27</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fell et al (2015)60</td>
<td>ML2-2</td>
<td>0.8</td>
<td>0.76</td>
<td>7.2</td>
</tr>
</tbody>
</table>

Abbreviations: LRRK2, leucine-rich repeat kinase 2; IV, intravenous; N/A, not available; NHP, non-human primate.

Analysis of the inhibitory effects of these two components on 185 diverse kinases showed that CZC-54252 inhibited ten kinases whereas CZC-25146 showed a cleaner profile, inhibiting only five kinases. In vivo, CZC-25146 had relatively good pharmacokinetic properties and an extensive distribution throughout animal body following intravenous injection into mice. Unfortunately, similar to LRRK2-IN-1, both CZC compounds failed to cross the BBB, displaying only 4% BBB penetration. Thus, although providing excellent tool compounds for assay development, further improvements were still required to generate compounds for in vivo testing.

Second-generation highly potent and selective compounds with BBB permeability

HG-10-102-1 was the first selective LRRK2 inhibitor reported to penetrate the BBB and inhibit LRRK2 activity in mouse brain. It has an IC50 close to LRRK2-IN-1 and completely inhibits LRRK2 in brain following intraperitoneal administration at a dose of 100 mg/kg. However, with lower doses of 10 and 30 mg/kg, HG-10-102-1 could only partially inhibit LRRK2 in brain. Another highly potent and selective LRRK2 inhibitor that achieved high exposure to brain was GSK2578215A. Having good BBB permeability and a half-life of 1.14 hours, it seemed to be a reasonable candidate. However, despite the high exposure, GSK2578215A failed to inhibit LRRK2 in brain when it was injected intraperitoneal into mice. The pyrrolopyrimidine JH-II-127 is another selective LRRK2 inhibitor, which like HG-10-102-1, caused...
complete inhibition of LRRK2 in mouse brain at 100 mg/kg, but only partial inhibition at 30 and 10 mg/kg doses.\(^\text{55}\)

Next, the small molecule GNE-7915 was reported following a high throughput screening system, revealing promising in vitro and in vivo profiles.\(^\text{56}\) This highly potent and selective LRRK2 inhibitor displayed low clearance values by rat hepatocytes, and a long half-life, in addition to high exposures in the periphery and brain throughout a 7-day dosing regimen in both rats and monkeys. Further development led to two more potent LRRK2 inhibitors, GNE-0877 and GNE-9605, both with enhanced brain penetration and cellular potency.\(^\text{57}\) These compounds demonstrated robust, dose-dependent inhibition of LRRK2 in the brain of transgenic mice expressing human LRRK2 G2019S protein.\(^\text{57}\) Both compounds also inhibited LRRK2 in the brain of nonhuman primates following oral administration.\(^\text{58}\)

PF-06447475 is another second-generation LRRK2 inhibitor with high potency, selectivity, and good BBB permeability properties.\(^\text{59}\) Although good brain permeability and availability, and moderate clearance were observed in rats, administration of 5 mg/kg of this compound to rat, dog, and nonhuman primates showed a poor oral pharmacokinetic profile in three species. Treatment of bacterial artificial chromosome transgenic WT LRRK2 and G2019S LRRK2 mice with PF-06447475, however, decreased the LRRK2 activity in brain and kidney after 90 minutes, even at a low dose of 3 mg/kg. Moreover, in a safety study, oral administration of PF-06447475 over 2 weeks was well tolerated at doses of 65 mg/kg.\(^\text{59}\)

Most recently, another novel potent, selective, brain penetrant LRRK2 inhibitor known as MLi-2 was reported.\(^\text{60}\) In vitro, MLi-2 presents a marked improvement in potency for G2019S LRRK2. In pharmacokinetic profile studies, MLi-2 had a mean maximum plasma concentration at 0.75 hours after 10 mg/kg oral administration and unbound fraction of 0.008 and 0.009 in plasma and brain, respectively. LRRK2 activity was decreased in brain following oral doses of MLi-2 in WT mice at 1 hour post-dose, with maximal suppression (>90% reduction) at 10 mg/kg. The development of LRRK2 blocking drugs has thus advanced to an extent that highly potent and selective compounds are now available to interrogate preclinical models of PD.

**Preclinical efficacy testing**

Key to advancing the translation of LRRK2 inhibitors to clinic is demonstrating proof-of-principle of LRRK2 inhibitor efficacy in preclinical PD-models. This is challenging, as unfortunately for PD research, preclinical models are rarely ideal. Recent efforts have focused on generating improved overexpression-based models using viral vectors, and also human-induced pluripotent stem cell models to determine any protective effect of the newer, more potent, and selective LRRK2 inhibitors.

**Viral vector rodent models**

The use of recombinant viral vectors to induce regional overexpression in adult rodent brain holds promise for developing quicker and more controlled models for studying potential PD therapeutics.\(^\text{61}\) The use of viral vectors also allows a ready comparison between pathogenic mutation and kinase inactive forms of LRRK2. Two studies, one using mice and the other rats, have demonstrated that viral mediated overexpression of G2019S LRRK2 via unilateral injection into the striatum can result in the progressive loss of substantia nigra dopaminergic neurons.\(^\text{48,62}\) In contrast, in mice, the overexpression of kinase inactive LRRK2 did not cause neuronal loss. Moreover, evidence was presented that the relatively nonselective LRRK2 inhibitor GW5074 could attenuate the LRRK2 G2019S-induced neuronal loss in mice.\(^\text{48}\) It would be important to see if such studies can be repeated with the more selective inhibitors now available. The use of LRRK2 viral vector models is not without challenge, however. The retrograde transport of viral particles from the striatum to the substantia nigra can be variable and indeed the vectors themselves can induce an inflammatory response with variable toxicity.\(^\text{63}\) Additionally there is no aggregation of α-synuclein in these LRRK2 overexpression models,\(^\text{52,63}\) potentially due to the short timeframes involved. Also the extent to which any motor phenotype develops has not been robustly explored.

In addition to direct overexpression of LRRK2, there is also much interest in determining the efficacy of LRRK2 inhibitors in more established models of α-synuclein overexpression. Of particular note are the experiments by Daher et al that show that the LRRK2 inhibitor, PF-06447475, effectively attenuates α-synuclein-induced dopaminergic neurodegeneration in WT and transgenic LRRK2 G2019S expressing rats.\(^\text{64}\) These experiments involved adeno-associated viral mediated α-synuclein overexpression via unilateral injection directly into the substantia nigra pars compacta. Daily oral dosing of PF-06447475 over 4 weeks markedly prevented the loss of dopaminergic neurons in both the substantia nigra and striatum and also reduced α-synuclein-mediated neurodegeneration.\(^\text{64}\) The results in WT rats are potentially exciting, as they suggest a protective role for LRRK2 inhibitors in idiopathic PD; however, the relationship between LRRK2
and α-synuclein is complex and the extent to which LRRK2 mediates α-synuclein pathology and if/how this relates to neural toxicity is very unclear.\textsuperscript{65,66}

**Pluripotent stem cell models**

The relatively new and rapidly accelerating field of induced pluripotent stem cells holds much promise for PD research. Such models allow for endogenous pathogenic variants to be studied in a neuronal context using primary human cells. The first step in the differentiation of induced pluripotent stem cells (IPSCs) to neurons is most often via neural stem cells, and a number of phenotypes have been uncovered for these cells that harbour LRRK2 mutations. Using a polymerase chain reaction-based assay to quantify mitochondrial DNA damage, Sanders et al could demonstrate increased damage in neural stem cells with either R1441C or G2019S mutations compared to nonmutation cells.\textsuperscript{67} Importantly, increased mitochondrial DNA damage could be reversed with zinc-finger nuclease-mediated correction of the G2019S mutation back to WT. This result is suggestive of mitochondrial dysfunction, and indeed, another study using G2019S and R1441C induced pluripotent stem cells-derived neural stem cells further reported reduced basal oxygen consumption, impaired mitochondrial dynamics, and increased sensitivity to valinomycin-induced stress in mutant cells.\textsuperscript{68} In addition to mitochondrial dysfunction, the LRRK2 G2019S mutation has also been associated with impaired nuclear envelope morphology, a phenotype often associated with cellular aging, and also impaired neural differentiation ability.\textsuperscript{69} Neural stem cells with the LRRK2 G2019S mutation have also been differentiated to dopamine neurons and show greater sensitivity to oxidative stress,\textsuperscript{70} as well as reduced neurite outgrowth\textsuperscript{71} and impaired autophagy.\textsuperscript{71,72} Moreover, a number of studies report abnormal and/or increased α-synuclein in G2019S neuronal cell lines compared to control.\textsuperscript{70–72} A number of these phenotypes have been reversed using early-generation inhibitors of LRRK2 such as LRRK2-IN1 and GW5074, and thus may serve as excellent models for testing the latest generation of specific and potent compounds.

**Preclinical safety testing**

To be efficacious for the treatment of PD, it is generally regarded that LRRK2 inhibitors will need to cross the BBB; however, it is established that other tissues, particularly lung, kidney, and certain peripheral immune cells robustly express LRRK2, potentially resulting in peripheral side effects (Figure 2). Indeed, brain tissue has far lower expression...
of LRRK2 than other tissues (~6.2-fold less than that of kidney). It is noteworthy that LRRK2 knockout mice have a normal life span; however, a number of studies have reported pathology in peripheral organs. Whether such pathologies are safety liabilities or indeed, are even observed in pharmacological studies, where the kinase activity of LRRK2 is only partially inhibited rather than genetically ablated, is currently under investigation.

**Kidney function**

Among different tissues, renal cells express the highest level of LRRK2 and therefore, not surprisingly, LRRK2 loss has the most striking effect on kidney. Macroscopically, darkening of kidney and its altered weight are the main reported features in genetically modified rats and mice with knockout of LRRK2 and less consistently, in kinase-dead LRRK2 mice (animals with kinase-inactivating point mutations). There is some evidence of impaired autophagy-lysosomal function in knockout and kinase-dead kidney of mice. Indeed, there are safety liabilities or indeed, are even observed in pharmacological inhibition of LRRK2, although with variable consistency across different models. First observed in knockout mice and rats, the major change in lung is abnormal accumulation of lamellar bodies in type II pneumocytes.

**Phospholipidosis**

Another reported side effect of loss/inhibited LRRK2 is phospholipidosis (PLD). In a study by Fuji et al, administration of LRRK2 inhibitors GNE-7915 and GNE-0877 in monkeys resulted in decreased urine di-22:6-BMP. Di-22:6-BMP is a phospholipid that is normally localized in the internal membrane of lysosomes and late endosomes, and is responsible for lysosomal degradation. Enlarged and increased numbers of lysosomes with stacked, whorled membranes and lipid were also observed in proximal tubules of LRRK2 knockout mice kidney, suggestive of accumulated phospholipid membranes in lysosomes. Drug-induced PLD is an acquired lysosomal storage disorder characterized by excessive accumulation of phospholipids and drugs in lysosomes in different tissues such as kidney, heart, and lungs. Since 1970, when the term PLD started to be used, more than 500 publications have reported PLD findings. It should be noted that PLD findings mainly include situations during preclinical studies in animals, and its significance in humans is unclear. Based on a FDA report, only a small number of PLD have induced toxicity in humans, because, first, it could be an adaptive response of the host to a drug, rather than a toxic manifestation, and second, the PLD seen in animals in preclinical studies is not predictive of similar findings in clinics. Thus, it is unclear if the observed PLD in animals with knockout or pharmacological inhibition of LRRK2 is a significant safety concern.

**Lamellar bodies in lung**

Lung is another organ in which LRRK2 has been implicated in pathological features. Unlike kidney tissue, pathological features in lung are observed with both knockout and pharmacological kinase inhibition of LRRK2, although with variable consistency across different models. First observed in knockout mice and rats, the major change in lung is abnormal accumulation of lamellar bodies in type II pneumocytes. Lamellar bodies are secretory lysosomal-related organelles measuring 0.2–0.3 μM in diameter. In pneumocytes, they secrete their stored contents (mainly phospholipids) known as pulmonary surfactants into the extracellular space. Enlargement of type II pneumocytes (defined as very slight) was observed in lungs of mice treated with MLi-2. Monkeys treated with GNE-7915 over a 7-day period also displayed increased size and number of lamellar bodies in lungs, similar to those seen in knockout animals, suggesting...
it to be an on-target side effect of LRRK2 inhibition.58 Apart from the accumulated lamellar bodies, which did not increase following a longer period of treatment (29 days), no other effect on the lungs was seen in monkeys. Interestingly, in contrast to monkeys, no pathological feature, including accumulation of lamellar bodies was seen in the lungs of mice and rats that were treated with GNE-7915 and GNE-0877,58 or mice treated with PF-06447475.64 The enlarged type II pneumocyte phenotype was also not observed in the lungs of LRRK2 mice with a kinase activating point mutation.21 Importantly, no changes have been reported in the size or weight of lungs in LRRK2 knockout, kinase inactive, or inhibitor-treated animals.73,75 As for kidney, it is therefore unclear if such a phenotype is a safety liability for human trials. Regardless, lung function could be readily monitored in early safety trials.

Inhibitor-induced degradation of LRRK2 protein

Another potential concern for LRRK2 inhibitors stems from observations that chronic LRRK2 inhibition often results in reduced expression of LRRK2 protein. Reduced levels of LRRK2 have been observed in mice with a kinase inactivating mutation71 and also in inhibitor-treated primates,58 mice,81 and primary human peripheral blood mononuclear cells.82 Mechanistically, LRRK2 inhibitor treatment appears to promote the ubiquitination of LRRK2 and consequently its proteosomal degradation.81 While quite high doses are required to achieve 20%–40% loss of LRRK2 protein, the consequences of continued pharmacological inhibition are still unclear. A reduction in LRRK2 levels with inhibitor treatment could explain the overlap in pathology seen in the lungs of knockout and inhibitor-treated animals. Moreover, loss of LRRK2 has been associated with increased susceptibility to inflammatory bowel disease85 and infection58 in mice. Thus, what happens to total LRRK2 levels under therapeutic dosing conditions would be useful to monitor.

Challenges for advancing to clinical trials

Despite more than 10 years of research since LRRK2 was first identified as a genetic cause of PD, many aspects of LRRK2 biology still remain unclear. How LRRK2 mutations lead to PD is unknown, and consequently what should/could be used as readouts of target engagement or inhibitor efficacy. Moreover, who should potentially be treated with LRRK2 kinase inhibitors and when?

Identifying the PD-relevant pathobiology

As major regulators of signal transduction pathways it is not unusual for protein kinases to mediate a number of biological responses. In this regard, LRRK2 may be no exception, having been linked to, among others, innate immunity, mitochondrial function, lysosomal trafficking and autophagy, WNT signaling, neurogenesis, synaptogenesis, transcriptional regulation and protein synthesis, cell death, and dopamine release (Figure 3). Trying to identify which aspects of LRRK2 biology are important for mediating PD is a major challenge. The recent identification of Rab GTPase proteins as bona fide LRRK2 substrates22 is a potentially exciting advance; however, the ~70-member family of Rab proteins themselves regulate many aspects of cell biology.85 Intriguingly, however, Rab7L1, also known as Rab29, has been genetically implicated in PD risk associated with the PARK16 locus.86,87 Studies in model organisms suggest that both LRRK2 and Rab7L1 work in the same biological pathway to regulate lysosomal function and cargo trafficking, particularly between the trans Golgi network and early/late endosomes.88–90 However, in vitro, LRRK2 has a marked preference for phosphorylating threonine residues over serine,91 and thus LRRK2 could only very weakly phosphorylate the serine containing Rab7L1 isoform.22 It still remains possible that LRRK2 could phosphorylate and regulate Rab7L1 in vivo, but under what conditions remains to be determined. Interestingly, Rab7L1 has also been implicated in innate immunity.

Figure 3 Potential mediators of LRRK2 pathobiology.

Notes: LRRK2 has been implicated in a variety of biological processes known to be perturbed in Parkinson’s disease. Rab GTPases, a number of which were recently identified as LRRK2 substrates, also contribute to the complex regulation of many PD-implicated biological processes.

Abbreviations: LRRK2, leucine-rich repeat kinase 2; PD, Parkinson’s disease.
immunity and pathogen clearance, another biological function involving LRRK2. Moreover, LRRK2 was found to interact with Rab10 and Rab2a, with LRRK2 and Rab2a in particular, being required for proper lysosome sorting in Paneth cells and protection from intestinal infection. Rab10, the most robustly phosphorylated of the identified LRRK2 substrates, is further involved in innate immunity through trafficking of toll-like receptors, the activation of which in turn leads to phosphorylation of LRRK2. Thus, lysosomal function and protein trafficking are likely to be key mediators of LRRK2 pathobiology with relevance for PD and also other LRRK2-associated diseases such as Crohn’s inflammatory bowel disease. However, understanding the specific context in which dysfunction leads to disease is still a major challenge.

**Better direct measures of target engagement**

The current gold standard for demonstrating LRRK2 inhibitor target engagement is measuring the loss of phosphorylation on serine residues 910, 935, 955, and 973 (Figure 4). These residues are located just before the leucine-repetitive domains in LRRK2 and, at least in the case of Ser910 and Ser935, serve to bind 14-3-3 adaptor proteins and potentially regulate the cellular localization of LRRK2. It has been unequivocally demonstrated in many cell and animal models that LRRK2 inhibitors cause a dose-dependent loss of phosphorylation at these sites, but exactly how this occurs is unknown. It is evident that these serine residues are not autophosphorylation sites, rather they are constitutively phosphorylated by other kinases whose identity has remained elusive. Therefore, rather than a direct effect, following inhibitor treatment LRRK2 must either negatively regulate the upstream kinase(s), or engage phosphatases. In regard to the latter, LRRK2 inhibitor treatment increases binding of protein phosphatase 1α to LRRK2 and promotes dephosphorylation of serines 910, 935, 955, and 973. However, what phosphorylates LRRK2 at these residues in the first place is largely unknown. Protein kinase A, casein kinase 1α, and the IkappaB kinases can all phosphorylate some or all of these LRRK2 serine residues when stimulated, but it is unclear if one or any of these are the kinase responsible for the constitutive LRRK2 serine phosphorylation. Thus, although effective, the complicated nature of using serines

---

**Figure 4 Measuring LRRK2 inhibitor target engagement.**

**Notes:** LRRK2 inhibitors cause the loss of constitutive phosphorylation on serine residues 910 and 935. However, these are not autophosphorylation sites and only serve as indirect measures of target engagement. Unlike S910 and S935, S1292 is a bona fide LRRK2 autophosphorylation site, but its low stoichiometry of phosphorylation makes it difficult to measure. LRRK2 can also directly phosphorylate certain Rab GTPase proteins such as Rab10, and these may serve as good direct measures of target engagement if robust assays can be developed.

**Abbreviation:** LRRK2, leucine-rich repeat kinase 2.
910, 935, 955, and/or 973 to infer target engagement requires careful validation. To some extent this has been demonstrated for peripheral blood mononuclear cells from idiopathic PD patients, where LRRK2 Ser910 and Ser935 phosphorylation were found to be invariant to age, gender, PD severity or duration, and L-Dopa medication, and were dephosphorylated to a similar extent with ex vivo LRRK2 inhibitor treatment. Nonetheless, it would be prudent to employ a second readout of target engagement for validation.

One possibility for a second readout is measuring LRRK2 Ser1292 phosphorylation, which unlike serines 910, 935, 955, and 973 is a bona fide autophosphorylation site. While there has been some success in measuring Ser1292 phosphorylation in exosomes purified from urine, the very low stoichiometry of phosphorylation at this residue has complicated its measurement in other biospecimens and highly sensitive assay platforms will be required. As well as potentially providing much needed insight into LRRK2 pathobiology, the recent identification of Rab GTPases as direct LRRK2 substrates may also hold promise for developing measures of target engagement.

Finally, it is also noteworthy that no central measures of inhibitor target engagement have yet been developed that would be suitable for human drug trials. Although LRRK2 is highly expressed in peripheral immune cells, its expression in cerebrospinal fluid is minimal and thus measuring LRRK2 phosphorylation problematic. Whether LRRK2 phosphorylated Rab proteins can be detected in cerebrospinal fluid remains to be determined, likewise whether imaging agents can be used to measure LRRK2 or its substrates in living brain. A central readout of target engagement will be important as it is generally regarded that brain penetration will be required to treat PD.

### When to treat and who

If LRRK2 blocking drugs are ultimately developed that are safe and efficacious in preclinical models then trials in humans would seemingly be warranted. Based on evidence to date, it would seem prudent to first trial such drugs in patients with activating LRRK2 mutations, particularly G2019S as this is by far the most common. A role for LRRK2 in neurogenesis has been proposed; however, there is no strong evidence that LRRK2 inhibitors will restore lost dopaminergic neurons and reverse PD. It will thus be important to determine if LRRK2 inhibitors should be used to try to slow down / halt the disease in already clinically diagnosed subjects (ie. already substantial loss of dopamine neurons). Or indeed whether LRRK2 inhibitors could / should be administered to asymptomatic mutation carriers to delay or even prevent the onset of neurodegeneration. The latter scenario is complicated by the incomplete penetrance of the G2019S mutation, which is estimated to be ~20%–50%, and therefore the need for earlier disease measures or predictors of which mutation carriers are likely to convert to clinical PD. A number of such measures have been proposed for asymptomatic LRRK2 mutation carriers, including increased peripheral inflammation, asymmetrical arm swing or gait changes when challenged, reduced nigrostriatal denervation, and subtle differences in nonmotor symptoms. However, lengthy longitudinal assessments are required to determine if any markers can be identified that robustly predict conversion to PD.

Another interesting prospect is whether LRRK2 inhibitors could also be used to treat more common idiopathic PD. Potential mediators of LRRK2 pathobiology, including lysosomal clearance defects, inflammation, and mitochondrial dysfunction, also clearly underlie idiopathic PD. PD by nature is heterogeneous, but LRRK2 G2019S-associated PD at least is largely similar to idiopathic PD in terms of age-of-onset, disease progression, and neuropathology. As outlined, LRRK2 is also genetically implicated in the increased risk of idiopathic PD. Thus, it is worth considering if LRRK2 inhibitors may have a broader utility; however, there is no evidence yet that LRRK2 activity is increased in idiopathic PD patients. This is largely due to the challenge of measuring LRRK2 activity in vivo, which will likely become feasible with the identification of LRRK2 substrates.

### Conclusion

Increasing evidence suggests that LRRK2 kinase activity contributes to its pathogenic role in PD. Recent studies suggest a converging theme of pathogenic LRRK2 mutations to increase both LRRK2 autophosphorylation and Rab GTPase substrate phosphorylation. Early preclinical studies also suggest a protective role of LRRK2 inhibitors in some models, but replication with the newer generation of highly potent and selective inhibitors is required. Moreover, preclinical models of PD themselves are not ideal and advances in developing models that recapitulate key PD features would enable better testing of LRRK2 inhibitors. Any mechanism of action of how LRRK2 inhibitors may work to protect neurons in preclinical models is also largely unknown. Emerging trends, however, suggest LRRK2 functions in the highly integrated pathways of...
autophagy/lysosomal function, mitochondrial function, and inflammation. LRRK2 inhibitors also perturb some of these functions in peripheral organs, particularly lung tissue, resulting in potentially unwanted side effects. Compared to many drugs though, LRRK2 inhibitors appear to be well tolerated. Further research to understand LRRK2 function and build evidence of LRRK2 inhibitor efficacy will aid in the translation of these drugs to potential clinical trials.

Acknowledgments

This research into PD is funded by the Michael J Fox Foundation for PD research, the Shake It Up Australia Foundation, Parkinson’s NSW, the University of New South Wales, and the National Health and Medical Research Council. We thank Heidi Cartwright for making the figures.

Disclosure

The authors report no conflicts of interest in this work.

References


